PIK3CA and glioblastoma: A recent study by Pandey et al. suggested that activating mutations in the phosphatidylinositol 3-kinase (PI3K) p110α subunit (PIK3CA gene) are potentially associated with a diminished or absent response to TTFields, as GBM patients harboring such mutations had a significantly shorter mOS compared to patients with wild type alleles when treated with TTFields, whereas this difference was not observed in the control group [13].